At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
erlotinibdrug
Likely dose
erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (EGFR) - (TRIGGER)
In Brief
A Phase 2 clinical trial evaluating erlotinib for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 50 participants across 10 sites.
Detailed Summary
This single-arm, open-label study evaluated the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic non-small cell lung cancer. Participants received daily oral doses of 150 mg Tarceva. The anticipated time on study treatment was 12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedJun 2011
Primary CompletionJun 2013
Study CompletionJan 2017
TodayJul 2026
First PostedJun 23, 2011
Enrollment StartMar 31, 2011
Primary CompletionJun 30, 2013
Study CompletionJan 31, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.0 years ago
Interventions
erlotinibdrug
150 mg orally once a day for 12 months